We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

GR Defect in Peripheral Blood Mononuclear Cells in COPD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00159237
First Posted: September 12, 2005
Last Update Posted: August 13, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
AstraZeneca
Information provided by:
Imperial College London
September 8, 2005
September 12, 2005
August 13, 2008
February 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00159237 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
GR Defect in Peripheral Blood Mononuclear Cells in COPD
GR Defect in Peripheral Blood Mononuclear Cells in COPD
T.to investigate a possible mechanism of the glucocorticosteroid receptors (GR) defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR- binding, interleukin production (IL-6/IL-8) and MKP-1 expression in peripheral blood mononuclear cells blood (PBMC)
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Chronic Obstructive Pulmonary Disease
Procedure: blood test
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
December 2008
Not Provided

Inclusion Criteria:

  • Patients with severe (stage III, Gold) to very severe (stage IV, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers
  • Written informed consent

Exclusion Criteria:

  • Current upper respiratory tract infections
  • Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
  • Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason
Sexes Eligible for Study: All
35 Years to 85 Years   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00159237
D5899N00007
Not Provided
Not Provided
Not Provided
Not Provided
Imperial College London
AstraZeneca
Principal Investigator: Sergei A Kharitonov, MD PhD Imperial College London
Imperial College London
August 2008